Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease
worldwide. NAFLD begins as a relatively benign hepatic steatosis which can evolve to non …

Dietary nutrients and the gut microbiota are increasingly recognized to cross-regulate and
entrain each other, and thus affect host health and immune-mediated diseases. Here, we …

Non-alcoholic fatty liver disease (NAFLD) has emerged as the hepatic component of the
metabolic syndrome and now seemingly affects one-fourth of the world population. Features …

Hepatic encephalopathy (HE) is a neurological disorder that occurs in patients with liver
insufficiency. However, its pathogenesis has not been fully elucidated. Pharmacotherapy is …

Minimal hepatic encephalopathy (MHE) is a frequent neurological and psychiatric
complication of liver cirrhosis. The precise pathogenesis of MHE is complicated and has yet …

Hepatic encephalopathy (HE) is a common complication of chronic liver disease,
characterized by an altered mental state and hyperammonemia. Insight into the brain …

Hepatic encephalopathy (HE) is a neuropsychiatric syndrome derived from metabolic
disorders due to various liver failures. Clinically, HE is characterized by hyperammonemia …

Hepatic encephalopathy (HE) is a neurological complication of hepatic dysfunction and
portosystemic shunting. It is highly prevalent in patients with cirrhosis and is associated with …

Psychobiotics are probiotics that have the characteristics of modulating central nervous
system (CNS) functions or reconciled actions by the gut–brain axis (GBA) through neural …

Hepatic encephalopathy (HE) is a potentially reversible neurocognitive complication of
cirrhosis. It has been reported in at least 30% of patients with cirrhosis and imposes a …